HIV p24 as Scaffold for presenting conformational HIV Env antigens

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Tagliamonte, Maria ^a   Marasco, Daniela ^b,c   Ruggiero, Alessia ^c   de Stradis, Angelo ^d   Tornesello, Maria Lina ^a   Totrov, Maxim ^e   Buonaguro, Franco Maria ^a   Buonaguro, Luigi ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c National Resource Council   (Italy)

^d Institute of Plant Virology   (Italy)

^e MOLSOFT LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENV ANTIGEN; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; MONOCLONAL ANTIBODY; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; MICROSCOPY, ELECTRON; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION;

EID: 84865094442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043318     Document Type: Article

References (52)

1. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L, (2010) Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect.Dis. 10: 305-316.
2. Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM, (2010) Viral evolution and escape during acute HIV-1 infection. J.Infect.Dis. 202 Suppl 2: S309-S314.
3. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. Journal of Virology 84: 1631-1636.
4. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS.Pathog. 6:.
5. Cheng-Mayer C, Homsy J, Evans LA, Levy JA, (1988) Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proceedings of National Academy of Science USA 85: 2815-2819.
6. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. Journal of Virology 81: 6548-6562.
7. Sather DN, Stamatatos L, (2010) Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 28 Suppl 2: B8-12.
8. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
9. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of Human Immunodeficiency Virus type 1. Journal of Virology 70: 1100-1108.
10. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67: 6642-6647.
11. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 17: 1757-1765.
12. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
13. Wu X, Yang ZY, Li Y, Hogerkorp CM, (2010) Schief WR, et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
14. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS.One. 5: e8805-.
15. Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, et al. (2006) Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. Journal of Virology 80: 6865-6872.
16. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, et al (2008) Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J.Mol.Biol. 375: 969-978.
17. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR, (2008) Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 381: 251-260.
18. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. Journal of Virology 78: 10724-10737.
19. Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, et al. (2006) Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. Journal of Virology 80: 1680-1687.
20. Zhou T, Xu L, Dey B, Hessell AJ, Van RD, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
21. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA, (2004) Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 12: 193-204.
22. Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, et al (2010) Elicitation of structure-specific antibodies by epitope scaffolds. Proc.Natl.Acad.Sci.U.S.A 107: 17880-17887.
23. Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, et al. (2011) Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS.One. 6: e16074-.
24. Chakraborty K, Durani V, Miranda ER, Citron M, Liang X, et al. (2006) Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Biochem.J. 399: 483-491.
25. Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, et al. (2010) Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 405: 513-523.
26. Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, et al. (2001) Neutralizing antiviral antibody responses. Adv.Immunol. 79: 1-53.
27. Bachmann MF, Hengartner H, Zinkernagel RM, (1995) T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? European Joutnal of Immunology 25: 3445-3451.
28. Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ, (2001) Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. Journal of Virology 75: 2130-2141.
29. Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, et al. (2004) Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infection and Immunity 72: 6519-6527.
30. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Journal of Virology 83: 10085-10095.
31. Buonaguro L, Tornesello ML, Buonaguro FM, (2010) Virus-Like Particles as Particulate Vaccines. Curr.HIV Res. 8: 299-399.
32. Vietheer PT, Boo I, Drummer HE, Netter HJ, (2007) Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir.Ther. 12: 477-487.
33. Buonaguro L, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, et al. (2001) High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Research. 49: 35-47.
34. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366: 245-262.
35. Wang BZ, Liu W, Kang SM, Alam M, Huang C, et al. (2007) Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. Journal of Virology 81: 10869-10878.
36. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, et al. (2009) X-ray structures of the hexameric building block of the HIV capsid. Cell 137: 1282-1292.
37. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM, (2011) Can HIV p24 Be a Suitable Scaffold for Presenting Env Antigens? Clin.Vaccine Immunol. 18: 2003-2004.
38. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
39. Abagyan R, Totrov M, Kuznetsov D, (1994) ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J.Comp.Chem. 15: 488-506.
40. von Schwedler UK, Stemmler TL, Klishko VY, Li S, Albertine KH, et al. (1998) Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17: 1555-1568.
41. Gross I, Hohenberg H, Krausslich HG, (1997) In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. Eur.J.Biochem. 249: 592-600.
42. Ganser-Pornillos BK, von Schwedler UK, Stray KM, Aiken C, Sundquist WI, (2004) Assembly properties of the human immunodeficiency virus type 1 CA protein. Journal of Virology 78: 2545-2552.
43. Martelli GP, Russo M, (1984) Use of thin sectioning for the visualization and identification of plant virus. Methods in Virology 8: 143-224.
44. Johnsson B, Lofas S, Lindquist G, (1991) Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal.Biochem. 198: 268-277.
45. Ganser-Pornillos BK, Yeager M, Sundquist WI, (2008) The structural biology of HIV assembly. Curr Opin.Struct.Biol. 18: 203-217.
46. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, et al. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. Journal of Virology 66: 7538-7542.
47. Ehrlich LS, Agresta BE, Carter CA, (1992) Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. Journal of Virology 66: 4874-4883.
48. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 22: 163-173.
49. Hinton HJ, Jegerlehner A, Bachmann MF, (2008) Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr Top Microbiol Immunol. 319: 1-15.
50. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ, (2000) B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol.Rev. 176: 154-170.
51. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF, (2002) Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. European Joutnal of Immunology 32: 818-825.
52. Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, et al. (1996) Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. European Joutnal of Immunology 26: 2595-2600.